|
1
|
Gottfried M, Keizman D, Mishaeli M and
Rabinovich Maimon N: The Current Approach To Advanced Lung Cancer.
Harefuah. 154(521–524): 539–540. 2015.(In Hebrew).
|
|
2
|
Xu P and Le Pechoux C: Chemoradiotherapy
for stage III non-small cell lung cancer: Have we reached the
limit? Chin Clin Oncol. 4:452015.PubMed/NCBI
|
|
3
|
Ahn JS, Ahn YC, Kim JH, Lee CG, Cho EK,
Lee KC, Chen M, Kim DW, Kim HK, Min YJ, et al: Multinational
randomized phase III trial with or without consolidation
chemotherapy using docetaxel and cisplatin after concurrent
chemoradiation in inoperable stage III non-small-cell lung cancer:
KCSG-LU05-04. J Clin Oncol. 33:2660–2666. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shen WY, Ji J, Zuo YS, Pu J, Xu YM, Zong
CD, Tao GZ, Chen XF, Ji FZ, Zhou XL, et al: Comparison of efficacy
for postoperative chemotherapy and concurrent radiochemotherapy in
patients with IIIA-pN2 non-small cell lung cancer: An early closed
randomized controlled trial. Radiother Oncol. 110:120–125. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sun JM, Ahn YC, Choi EK, Ahn MJ, Ahn JS,
Lee SH, Lee DH, Pyo H, Song SY, Jung SH, et al: Phase III trial of
concurrent thoracic radiotherapy with either first-or third-cycle
chemotherapy for limited-disease small-cell lung cancer. Ann Oncol.
24:2088–2092. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bourgier C, Lacombe J, Solassol J, Mange
A, Pèlegrin A, Ozsahin M and Azria D: Late side-effects after
curative intent radiotherapy: Identification of hypersensitive
patients for personalized strategy. Crit Rev Oncol Hematol.
93:312–319. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Noguchi Y, Nishimura R, Kawara H, Omori K,
Matsumoto K, Tokuyama Y, Uchiyama K and Shimizu Y: Survey of
current status of adverse ocular reactions to paclitaxel and a
retrospective analysis for aiding in early detection of adverse
reactions. Gan To Kagaku Ryoho. 40:819–822. 2013.PubMed/NCBI
|
|
8
|
Linam J and Yang LX: Recent developments
in radiosensitization. Anticancer Res. 35:2479–2485.
2015.PubMed/NCBI
|
|
9
|
Sheppard DW and MacRitchie JA: Building in
molecular diversity for targeted libraries. Drug Discov Today
Technol. 10:e461–e466. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Milano GA: Targeted therapy in non-small
cell lung cancer: A focus on epidermal growth factor receptor
mutations. Chin Clin Oncol. 4:472015.PubMed/NCBI
|
|
11
|
Ricciuti B, Leonardi GC, Metro G, Grignani
F, Paglialunga L, Bellezza G, Baglivo S, Mencaroni C, Baldi A,
Zicari D and Crinò L: Targeting the KRAS variant for treatment of
non-small cell lung cancer: Potential therapeutic applications.
Expert Rev Respir Med. 10:53–68. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Müller-Decker K: Cyclooxygenase-dependent
signaling is causally linked to non-melanoma skin carcinogenesis:
Pharmacological, genetic, and clinical evidence. Cancer Metastasis
Rev. 30:343–361. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tsujii M: Cyclooxygenase, cancer stem
cells and DNA methylation play important roles in colorectal
carcinogenesis. Digestion. 87:12–16. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lee JY, Myung SK and Song YS: Prognostic
role of cyclooxygenase-2 in epithelial ovarian cancer: A
meta-analysis of observational studies. Gynecol Oncol. 129:613–619.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Magnowska M, Zaborowski M, Surowiak P,
Nowak-Markwitz E, Zabel M and Spaczyński M: COX-2 expression
pattern is related to ovarian cancer differentiation and prognosis,
but is not consistent with new model of pathogenesis. Ginekol
Polska. 85:335–341. 2014. View
Article : Google Scholar
|
|
16
|
Liu R, Xu KP and Tan GS: Cyclooxygenase-2
inhibitors in lung cancer treatment: Bench to bed. Eur J Pharmacol.
769:127–133. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Regulski M, Regulska K, Prukala W,
Piotrowska H, Stanisz B and Murias M: COX-2 inhibitors: A novel
strategy in the management of breast cancer. Drug Discov Today.
21:598–615. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Amir M and Agarwal H: Role of COX-2
selective inhibitors for prevention and treatment of cancer.
Pharmazie. 60:563–570. 2005.PubMed/NCBI
|
|
19
|
Kalgutkar AS and Zhao Z: Discovery and
design of selective cyclooxygenase-2 inhibitors as non-ulcerogenic,
anti-inflammatory drugs with potential utility as anti-cancer
agents. Curr Drug Targets. 2:79–106. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu R, Xu KP and Tan GS: Cyclooxygenase-2
inhibitors in lung cancer treatment: Bench to bed. Eur J Pharmacol.
769:127–133. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mohammadinejad P, Arya P, Esfandbod M,
Kaviani A, Najafi M, Kashani L, Zeinoddini A, Emami SA and
Akhondzadeh S: Celecoxib versus diclofenac in mild to moderate
depression management among breast cancer patients: A double-blind,
placebo-controlled, randomized trial. Ann Pharmacother. 49:953–961.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Steinauer KK, Gibbs I, Ning S, French JN,
Armstrong J and Knox SJ: Radiation induces upregulation of
cyclooxygenase-2 (COX-2) protein in PC-3 cells. Int J Radiat Oncol
Biol Phys. 48:325–328. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hida T, Yatabe Y, Achiwa H, Muramatsu H,
Kozaki K, Nakamura S, Ogawa M, Mitsudomi T, Sugiura T and Takahashi
T: Increased expression of cyclooxygenase 2 occurs frequently in
human lung cancers, specifically in adenocarcinomas. Cancer Res.
58:3761–3764. 1998.PubMed/NCBI
|
|
24
|
Isoherranen K, Punnonen K, Jansen C and
Uotila P: Ultraviolet irradiation induces cyclooxygenase-2
expression in keratinocytes. Br J Dermatol. 140:1017–1022. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Raju U, Nakata E, Yang P, Newman RA, Ang
KK and Milas L: In vitro enhancement of tumor cell radiosensitivity
by a selective inhibitor of cyclooxygenase-2 enzyme: Mechanistic
considerations. Int J Radiat Oncol Biol Phys. 54:886–894. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Blanco R, Maestu I, de la Torre MG,
Cassinello A and Nuñez I: A review of the management of elderly
patients with non-small-cell lung cancer. Ann Oncol. 26:451–463.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Guy JB, Rancoule C, Méry B, Espenel S,
Wozny AS, Simonet S, Vallard A, Alphonse G, Ardail D,
Rodriguez-Lafrasse C and Magné N: Radiosensitivity and/or
radioresistance of head and neck cancers: Biological angle. Bull
Cancer. 103:41–47. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chang L, Graham PH, Ni J, Hao J, Bucci J,
Cozzi PJ and Li Y: Targeting PI3K/Akt/mTOR signaling pathway in the
treatment of prostate cancer radioresistance. Crit Rev Oncol
Hematol. 96:507–517. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chang L, Graham P, Hao J, Bucci J, Malouf
D, Gillatt D and Li Y: Proteomics discovery of radioresistant
cancer biomarkers for radiotherapy. Cancer Lett. 369:289–297. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Spector AA and Kim HY: Discovery of
essential fatty acids. J Lipid Res. 56:11–21. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Frungieri MB, Calandra RS, Mayerhofer A
and Matzkin ME: Cyclooxygenase and prostaglandins in somatic cell
populations of the testis. Reproduction. 149:R169–R180. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Claar D, Hartert TV and Peebles RS Jr: The
role of prostaglandins in allergic lung inflammation and asthma.
Expert Rev Respir Med. 9:55–72. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sugimoto Y, Inazumi T and Tsuchiya S:
Roles of prostaglandin receptors in female reproduction. J Biochem.
157:73–80. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tjandrawinata RR, Dahiya R and
Hughes-Fulford M: Induction of cyclo-oxygenase-2 mRNA by
prostaglandin E2 in human prostatic carcinoma cells. Br J Cancer.
75:1111–1118. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Williams CS, Mann M and DuBois RN: The
role of cyclooxygenases in inflammation, cancer, and development.
Oncogene. 18:7908–7916. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sano H, Kawahito Y, Wilder RL, Hashiramoto
A, Mukai S, Asai K, Kimura S, Kato H, Kondo M and Hla T: Expression
of cyclooxygenase-1 and-2 in human colorectal cancer. Cancer Res.
55:3785–3789. 1995.PubMed/NCBI
|
|
37
|
Azer SA: Overview of molecular pathways in
inflammatory bowel disease associated with colorectal cancer
development. Eur J Gastroenterol Hepatol. 25:271–281. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Harris RE, Beebe J and Alshafie GA:
Reduction in cancer risk by selective and nonselective
cyclooxygenase-2 (COX-2) inhibitors. J Exp Pharmacol. 4:91–96.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Cathcart MC, O'Byrne KJ, Reynolds JV,
O'Sullivan J and Pidgeon GP: COX-derived prostanoid pathways in
gastrointestinal cancer development and progression: Novel targets
for prevention and intervention. Biochim Biophys Acta. 1825:49–63.
2012.PubMed/NCBI
|
|
40
|
Wang X, Baek SJ and Eling T: COX
inhibitors directly alter gene expression: Role in cancer
prevention? Cancer Metastasis Rev. 30:641–657. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Nalamachu S, Pergolizzi JV, Raffa RB,
Lakkireddy DR and Taylor R Jr: Drug-drug interaction between NSAIDS
and low-dose aspirin: A focus on cardiovascular and GI toxicity.
Expert Opin Drug Saf. 13:903–917. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Masferrer JL, Isakson PC and Seibert K:
Cyclooxygenase-2 inhibitors: A new class of anti-inflammatory
agents that spare the gastrointestinal tract. Gastroenterol Clin
North Am. 25:363–372. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Pairet M and Engelhardt G: Distinct
isoforms (COX-1 and COX-2) of cyclooxygenase: Possible
physiological and therapeutic implications. Fundam Clin Pharmacol.
10:1–17. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Grösch S, Tegeder I, Niederberger E,
Bräutigam L and Geisslinger G: COX-2 independent induction of cell
cycle arrest and apoptosis in colon cancer cells by the selective
COX-2 inhibitor celecoxib. FASEB J. 15:2742–2744. 2001.PubMed/NCBI
|
|
45
|
Kern MA, Schubert D, Sahi D, Schöneweiss
MM, Moll I, Haugg AM, Dienes HP, Breuhahn K and Schirmacher P:
Proapoptotic and antiproliferative potential of selective
cyclooxygenase-2 inhibitors in human liver tumor cells. Hepatology.
36:885–894. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Li M, Wu X and Xu XC: Induction of
apoptosis by cyclo-oxygenase-2 inhibitor NS398 through a cytochrome
C-dependent pathway in esophageal cancer cells. Int J Cancer.
93:218–223. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Elder D, Halton DE, Hague A and Paraskeva
C: Induction of apoptotic cell death in human colorectal carcinoma
cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal
anti-inflammatory drug: Independence from COX-2 protein expression.
Clin Cancer Res. 3:1679–1683. 1997.PubMed/NCBI
|
|
48
|
Amirghahari N, Harrison L, Smith M, Rong
X, Naumann I, Ampil F, Shi R, Glass J and Nathan CO: NS 398
radiosensitizes an HNSCC cell line by possibly inhibiting
radiation-induced expression of COX-2. Int J Radiat Oncol Biol
Phys. 57:1405–1412. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Kang KB, Wang TT, Woon CT, Cheah ES, Moore
XL, Zhu C and Wong MC: Enhancement of glioblastoma radioresponse by
a selective COX-2 inhibitor celecoxib: Inhibition of tumor
angiogenesis with extensive tumor necrosis. Int J Radiat Oncol Biol
Phys. 67:888–896. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Lang S, Lauffer L, Clausen C, Löhr I,
Schmitt B, Hölzel D, Wollenberg B, Gires O, Kastenbauer E and
Zeidler R: Impaired monocyte function in cancer patients:
Restoration with a cyclooxygenase-2 inhibitor. FASEB J. 17:286–288.
2003.PubMed/NCBI
|
